Strategic CMC for Non-Virally Delivered RNA Therapeutics
EXECUTIVE SUMMARY
Programmatic Asset
CELL & GENE | RNA | BIOLOGICS
This summary outlines strategic Chemistry, Manufacturing, and Controls (CMC) considerations for RNA therapeutic programs targeting Swissmedic approval. It focuses on the specific analytical and manufacturing data required within an Investigational Medicinal Product Dossier (IMPD) for lipid nanoparticle (LNP) and other non-viral delivery systems. Key areas include rigorous characterization of novel LNP components, defining product quality attributes (CQAs) for the RNA payload, and developing phase-appropriate potency assays to de-risk the regulatory submission.
Frequently Asked Questions
What are the primary CMC sections Swissmedic scrutinizes in an Investigational Medicinal Product Dossier (IMPD) for an mRNA therapeutic?
Swissmedic places significant emphasis on the characterization and control of both the active substance (the mRNA) and the delivery vehicle (e.g., Lipid Nanoparticles). Your IMPD must provide robust data on mRNA integrity, purity (especially dsRNA contaminants), and 5′ capping efficiency. For the LNP, detailed specifications for lipid components, particle size, polydispersity, and encapsulation efficiency are required.
How do you approach CMC for novel LNP formulations to satisfy European regulatory expectations?
For novel LNP therapies, the CMC strategy must treat the delivery system with the same rigor as the active payload. This involves comprehensive characterization of any non-compendial excipients, such as ionizable lipids or helper lipids, and their impact on biodistribution and stability. As demonstrated in recent preclinical work with siloxane-incorporated LNPs (PMID: 39354147), the specific lipid composition directly governs tissue targeting and biological activity, making this a focal point for regulatory review.
What level of analytical validation is expected for RNA therapeutic potency assays in early-phase Swissmedic submissions?
For early-phase submissions, Swissmedic expects potency assays to be qualified and demonstrated as suitable for their intended purpose. While full GxP validation is not required, the assay must be robust, reproducible, and reflect the therapeutic’s mechanism of action (MOA). This includes demonstrating a dose-response relationship and the ability to detect changes in product quality.
Proven Intelligence in Regulatory CMC for RNA Therapeutics
A tailored preclinical and manufacturing strategy is fundamental for any next-generation therapeutic. For RNA-based programs targeting Swissmedic approval, the Investigational Medicinal Product Dossier (IMPD) requires a CMC package that addresses the unique attributes of both the RNA payload and its delivery system.
The analytical strategy must be capable of distinguishing between biological effects caused by the delivery vehicle and those originating from the RNA payload itself. Early preclinical data from other modalities has shown that payload-mediated cellular toxicity can occur independently of the vector (PMID: 21542669). A robust CMC program anticipates this regulatory concern by developing specific assays to characterize product-related impurities, such as double-stranded RNA, which can trigger unintended immunological responses.
Characterizing the Delivery System and Payload
For therapeutics utilizing non-viral vectors like Lipid Nanoparticles (LNPs), Swissmedic and other European authorities expect a deep understanding of the formulation’s physical and chemical properties.
-
LNP Component Control: The identity, purity, and specifications for each lipid component (ionizable lipids, helper lipids, cholesterol, PEG-lipids) must be established. For novel excipients, additional safety data may be required.
-
Particle Attributes: Key quality attributes for the final LNP formulation include particle size, polydispersity index (PDI), zeta potential, and encapsulation efficiency. These parameters directly influence the stability, in vivo biodistribution, and efficacy of the therapeutic.
-
RNA Payload Integrity: The CMC package must include data from assays confirming the integrity, identity, and purity of the RNA payload post-encapsulation. This ensures the manufacturing process does not compromise the active substance.
The scientific leadership at Franklin Biolabs carries a track record that includes a 100% successful IND rate since 2019, established prior to the company’s formal launch in 2024. This history provides the foundational experience needed to navigate complex regulatory submissions.
This leadership is supported by scientific teams with demonstrated expertise across the full scope of vector production and analytics.
Navigating the specific requirements of agencies like Swissmedic demands a scientific extension with direct experience. Our teams build phase-appropriate CMC programs that generate the precise data needed to support IMPD submissions, helping sponsors move from discovery to clinical evaluation within an 18-24 month timeline. Our >100,000 sq ft of specialized laboratory and housing facilitiesprovide the infrastructure to execute these integrated programs.
This strategic approach connects directly to our broader capabilities in Vector | CMC | Analytics Services, ensuring a cohesive development path.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.